MARKET

CTIC

CTIC

CTi Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.380
0.000
0.00%
Closed 16:00 01/17 EST
OPEN
1.390
PREV CLOSE
1.380
HIGH
1.400
LOW
1.350
VOLUME
81.33K
TURNOVER
--
52 WEEK HIGH
1.930
52 WEEK LOW
0.6305
MARKET CAP
80.01M
P/E (TTM)
-2.5819
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CTIC and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CTIC News

  • NIO, SDRL, CTIC and AGRX among midday movers
  • Seeking Alpha - Article.12/24/2019 16:17
  • CTIC, AKRX, QIWI and INPX among midday movers
  • Seeking Alpha - Article.12/18/2019 17:41
  • Is CTI BioPharma Corp. (CTIC) A Good Stock To Buy ?
  • Insider Monkey.12/16/2019 10:58
  • CTI BioPharma Highlights Presentation Of Data Supporting Pacritinib's Benefit In Myelofibrosis Patients With Severe Thrombocytopenia At ASH
  • Benzinga.12/09/2019 15:31

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About CTIC

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
More

Webull offers CTI BioPharma Corp (CTIC) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.